Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Owonikoko, Taofeek Kunle
160  Ergebnisse:
Personensuche X
?
1

Efficacy and safety of immune checkpoint blockade in self‐i..:

Nazha, Bassel ; Goyal, Subir ; Chen, Zhengjia...
Cancer.  126 (2020)  23 - p. 5040-5049 , 2020
Link: https://doi.org/10.1002/..
 
?
2

First-in-human multicenter phase I study of BMS-936561 (MDX..:

Owonikoko, Taofeek Kunle ; Hussain, Arif ; Stadler, Walter Michael...
Cancer Chemotherapy and Pharmacology.  77 (2015)  1 - p. 155-162 , 2015
Link: https://doi.org/10.1007/..
 
?
3

Genetische Heterogenität in Adenokarzinomen des Ösophagus..:

- [Elektronische Ressource] . , 2000
Link: http://d-nb.info/9618288..
 
?
4

Efficacy and safety of immune checkpoint blockade in self-i..:

Nazha, Bassel ; Goyal, Subir ; Chen, Zhengjia...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717500/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
5

SCLC Classification by Platinum Sensitivity in the Era of I..:

Owonikoko, Taofeek K.
Journal of Thoracic Oncology.  19 (2024)  2 - p. 193-195 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Shifting Sociodemographic Characteristics of a Phase I Clin..:

Lalonde, Chloe S ; Switchenko, Jeffrey M ; Behera, Madhusmita...
The Oncologist.  28 (2023)  12 - p. 1055-1063 , 2023
Link: https://doi.org/10.1093/..
 
?
7

Concurrent Androgen Deprivation Therapy for Prostate Cancer..:

Nazha, Bassel ; Zhang, Chao ; Chen, Zhengjia..
Cancers.  14 (2022)  13 - p. 3206 , 2022
Link: https://doi.org/10.3390/..
 
?
8

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI ..:

Wermke, Martin ; Felip, Enriqueta ; Gambardella, Valentina...
Future Oncology.  18 (2022)  24 - p. 2639-2649 , 2022
Link: https://doi.org/10.2217/..
 
?
9

Serum glycomic profile as a predictive biomarker of recurre..:

Kudelka, Matthew R. ; Lasanajak, Yi ; Smith, David F....
Cancer Medicine.  12 (2022)  6 - p. 6768-6777 , 2022
Link: https://doi.org/10.1002/..
 
?
10

A Multicenter Randomized Phase II Study of Single Agent Eff..:

Bauman, Julie E. ; Chen, Zhengjia ; Zhang, Chao...
Cancers.  14 (2022)  11 - p. 2639 , 2022
Link: https://doi.org/10.3390/..
 
?
11

Overcoming acquired resistance to third-generation EGFR inh..:

Ma, Guangzhi ; Deng, Yunfu ; Qian, Luxi...
Oncogene.  41 (2022)  12 - p. 1691-1700 , 2022
Link: https://doi.org/10.1038/..
 
?
12

Systematic discovery of mutation-directed neo-protein-prote..:

Mo, Xiulei ; Niu, Qiankun ; Ivanov, Andrey A....
Cell.  185 (2022)  11 - p. 1974-1985.e12 , 2022
Link: https://doi.org/10.1016/..
 
?
13

Assessment of hyperprogression versus the natural course of..:

Kang, Yoon-Koo ; Reck, Martin ; Nghiem, Paul...
Journal for ImmunoTherapy of Cancer.  10 (2022)  4 - p. e004273 , 2022
Link: https://doi.org/10.1136/..
 
?
14

Comparing VIP and PD‐L1 expression as cancer biomarkers:

Liu, Jojo Y. ; Zhang, Hanwen ; Ravindranathan, Sruthi...
ImmunoMedicine.  2 (2022)  2 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
15

Physician Communication and Patient Understanding of Molecu..:

Blee, Shannon M. ; Shah, Rachel Pocock ; Pinheiro, Ana P.M....
The Oncologist.  26 (2021)  11 - p. 934-940 , 2021
Link: https://doi.org/10.1002/..
 
1-15